Abstract
There have been substantial advances in treatment options for multidrug-resistant and rifampicin-resistant tuberculosis. Just a few years ago, a typical patient faced months of painful injections, life-changing adverse effects, and a very small chance of cure. This year, WHO announced forthcoming updates to global guidelines including 6-month and 9-month all-oral regimens for treatment of multidrug-resistant and rifampicin-resistant tuberculosis.1 In the context of these rapidly changing options for treating multidrug-resistant and rifampicin-resistant tuberculosis and persisting high costs of newer drugs such as bedaquiline, countries are facing difficult decisions about when and how to incorporate new drug regimens into national guidelines, and the economic effects of new regimens will be a key consideration in their uptake.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
